ProCE Banner Activity

OlympiAD: PARP Inhibitor Olaparib Monotherapy in HER2-Negative, BRCA-Mutated MBC

Slideset Download
Conference Coverage
Study data showed significantly prolonged PFS and a lower rate of high-grade adverse events with olaparib monotherapy vs CT.

Released: June 08, 2017

Expiration: June 07, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology